Condition: Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) · Sponsor: University Health Network, Toronto
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.
This description comes directly from the study's public registry record.
Lillian Siu, MD · 416-946-4501 · tip@uhn.ca
Minge Xu · 416-946-4501 · Minge.Xu@uhn.ca
Always discuss trial participation with your own doctor first.
| Princess Margaret Cancer Centre | Toronto, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05414032